RALEIGH, N.C., April 06, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced a strategic collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. Through this collaboration, INC and CISCRP will jointly develop and implement educational initiatives designed to bring greater awareness to the importance of clinical trial participation in advancing public health.
"Continuing to make patients valued partners in the clinical research process is vital to accelerating the delivery of new medicines to market,” said Clare Grace, PhD, Vice President, Site and Patient Access. “CISCRP has been doing great work in this area for more than a decade and INC Research is proud to support their efforts to further increase awareness of the critical role patients play in clinical research and the value that this research brings to the development of new therapies. By furthering the connection that patients have with the clinical research community, we can better understand their perceptions about clinical research and the barriers that are potentially preventing them from participating in trials for which they may be suited.”
"Without clinical trial participants, new medicines and discoveries simply wouldn’t be possible," said CISCRP Founder Ken Getz. "It is essential that we engage patients and their local health care community as partners in the drug development process. We are very excited about entering into this collaboration with INC Research to raise public awareness about clinical research, to educate the patient community and to ultimately strengthen patient engagement.”
As a main component of the strategic collaboration, INC Research and CISCRP will co-host a ground-breaking event in September 2016 called the “Inspiring Hope” Ideathon. This unique event will bring together industry leaders and pioneers along with advocacy groups and is designed to generate new ideas and discuss innovative ways to help raise awareness of clinical research. To register interest in participating or for more information on the event, please email [email protected]. In addition, INC Research will sponsor CISCRP programs and events, such as AWARE for All and Medical Heroes, throughout the year as well as collaborate on the development of future patient awareness events. The Company will work with CISCRP to leverage findings from the 2015 CISCRP Perceptions & Insights survey to improve awareness of volunteer perceptions, motivations and experiences with clinical research/inform strategies that incorporate the patient voice into trial design.
For the last two years, INC Research and CISCRP have co-chaired Patients as Partners in Clinical Trials, an annual conference designed for clinical trial executives in pharma and biotech, directors in patient advocacy, patients involved in clinical trials, academia, government and service providers who are looking to incorporate the patient perspective throughout the clinical trial process.
About CISCRP
The Center for Information and Study on Clinical Research Participation (CISCRP) is a first-of-its-kind nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media, and policy makers about clinical research and the role each party plays in the process. CISCRP provides free education and outreach to the general public and patient communities. Visit www.CISCRP.org for more information or to support CISCRP.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: [email protected] Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: [email protected]


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



